As geopolitical tensions rise, Calian continues to deliver mission-critical healthcare to support Canada’s military readinessOTTAWA, Ontario, July 08, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today announced a $250 million amendment to its Health Care Provider Recruitment (HCPR) contract with the Department of National Defence (DND). This amendment reinforces Calian’s ...

Core Insights - Nutex Health Inc. has received multiple community-driven accolades for its healthcare delivery in the second quarter of 2025, highlighting its commitment to patient care and community service [1][2]. Company Overview - Nutex Health Inc. is a physician-led integrated healthcare delivery system with 24 micro hospitals and hospital outpatient departments across 11 states, focusing on primary care and risk-bearing physician networks [1][4]. - The company was founded in 2011 and is headquartered in Houston, Texas, operating through two divisions: Hospital Division and Population Health Management Division [4][5]. Awards and Recognition - The Colony ER Hospital was awarded "Best Urgent/Emergency Care" in April 2025 by The Colony Chamber of Commerce [3]. - Wylie ER received the title of "Best Emergency Room" in April 2025 from C&S Media [3]. - Dr. Michael Brin from Milwaukee ER & Hospital and Dr. Maley from Tucson ER & Hospital both received "Top Doc Awards" in June 2025 from respective local publications [3]. - Texarkana Emergency Center & Hospital was recognized for "Best Emergency Care/Hospital" in June 2025 by Bowie County Tribune and also received "Best Emergency Care" in the "2025 Best of Texarkana Readers' Choice Awards" [3]. - Dr. Tom Vo, the CEO of Nutex Health, was honored as "Most Admired CEO" in June 2025 by the Houston Business Journal [3]. Commitment to Patient Care - The company emphasizes that its recognition stems from a primary focus on patient care, with awards voted on by the communities it serves, reflecting high patient satisfaction and service quality [2][3].

Employment in the mental health industry has grown at a rapid pace since 2020, thanks in part to federal grants funding training programs to expand and improve the workforce https://t.co/LRBCVy4Qwr ...

Core Insights - The Cigna Group Foundation has announced a new round of grants totaling $9 million over three years, focusing on improving the mental health of military veterans by addressing social determinants of health, particularly housing stability [1][6][8] Grant Program Details - The 2025 grant application is open for eligible organizations in select states, closing on August 7, 2025 [2] - The foundation prioritizes grants in regions with high social determinant of health risks, including Arizona, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey, Pennsylvania, Tennessee, and Texas [3][6] - Goals of the grant program include increasing permanent housing for veterans, improving housing affordability through rental or mortgage assistance, and enhancing wraparound services for veterans transitioning from shelters [3][6] Veteran Mental Health Context - Military veterans face a higher risk of homelessness, with approximately 40,000 veterans without shelter on any given night, and a 7% increase in homelessness among veterans reported from 2022 to 2023 [4][6] Previous Funding Impact - In 2024, the first year of the grant program, $3 million was distributed to 23 organizations to support local veterans, focusing on stability and mental health [5][6] - Examples of funded initiatives include the Veterans Rapid Rehousing Program in Texas and financial assistance for veteran homeowners facing foreclosure in Tennessee [7] Broader Philanthropic Commitment - The Cigna Group Foundation has committed over $27 million in grants over three years to address youth and veteran mental health and reduce barriers to health equity [8]

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Core Viewpoint - Centene Corporation is facing potential legal claims regarding violations of federal securities laws and unlawful business practices following a significant drop in stock price after withdrawing its 2025 earnings guidance [1][2]. Group 1: Company Performance - On July 2, 2025, Centene's stock price fell over 39.5% during intraday trading after the company announced the withdrawal of its 2025 earnings guidance due to higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - The company indicated that its Medicaid business has seen an increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Centene on behalf of its stockholders, focusing on whether the company has violated federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information regarding these claims [3].

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit from investors who purchased securities during the specified Class Period, alleging misleading statements regarding Medicaid cost trends and financial guidance [1][3]. Group 1: Class Action Details - The class action represents investors who bought Elevance securities between April 18, 2024, and October 16, 2024, with a deadline of July 11, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance's management misled investors about the Medicaid redetermination process, claiming they were monitoring cost trends and that premium rates were adequate [3]. - It is claimed that the redetermination process resulted in a higher-risk Medicaid population, which was not accurately reflected in Elevance's financial projections or rate negotiations for 2024 [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of misleading statements and deceptive practices related to the promotion of illegitimate products, which may jeopardize its collaboration with Novo Nordisk [3][4]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from April 29, 2025, to June 23, 2025, Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [3]. - It is alleged that this conduct created a substantial risk of termination of the company's collaboration with Novo Nordisk [3]. - The defendants' positive statements regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis due to these issues [3]. Class Action Details - Shareholders who purchased HIMS shares during the specified class period are encouraged to register for the class action, with a deadline set for August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in this class action [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors regarding the monitoring of cost trends related to the Medicaid "redetermination" process and assured that premium rates were sufficient to cover rising costs [4]. - It was revealed that the redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has been adjour ...